'On standalone basis
Quarter ended June 2025 compared with Quarter ended June 2024.
Net sales (including other operating income) of Sanofi India has declined 12.34% to Rs 406.30 crore. Operating profit margin has declined from 24.96% to 23.36%, leading to 17.98% decline in operating profit to Rs 94.90 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 19.69% to 21.03%. Purchase of finished goods cost fell from 22.18% to 12.06%. Employee cost increased from 14.44% to 15.20%. Other expenses rose from 15.95% to 19.57%.
Other income up 81.25% to Rs 8.7 crore. PBIDT fell 14.02% to Rs 103.6 crore. Provision for interest remained nil. Loan funds declined from Rs 22.10 crore as of 30 June 2024 to Rs 20.90 crore as of 30 June 2025. Inventories declined from Rs 356.20 crore as of 30 June 2024 to Rs 271.70 crore a...
Pleaselogin & subscribe to view the full report.
More Reports
|
|